This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06643728 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 252 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight |
| Interventions | Bimagrumab; Tirzepatide; Bimagrumab Placebo; Tirzepatide Placebo |
| Start | Oct 21, 2024 |
| Primary completion | Jan 16, 2026 |
| Study completion | Jan 2027 |
| Results posted | Not yet |
| Registry last updated | May 26, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 24 |
10 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
